Findings of Misconduct in Science, 38836-38837 [E7-13703]

Download as PDF 38836 Federal Register / Vol. 72, No. 135 / Monday, July 16, 2007 / Notices Trans # Acquiring Acquired Entities ......................... ......................... ......................... ......................... ......................... ......................... William H. Gates, III .......................... News Corporation .............................. Kellwood Company ........................... Perry Partners International, Inc ....... Perry Partners, L.P ............................ Pro Acquisition Corporation .............. Dynegy Inc ........................................ Photobucket.com, Inc ........................ Hanna Andersson Corporation .......... Universal American Financial Corp ... Universal American Financial Corp ... The Home Depot, Inc ........................ 20071607 ......................... TD AMERITRADE Holding Corporation. Fiserv, Inc .......................................... CoGen Lyondell, LLC. Photobucket.com, Inc. Hanna Andersson Corporation. Universal American Financial Corp. Universal American Financial Corp. CND Holdings, Inc., HD Supply, Inc., Homer TLC, Inc. Fiserv Trust Company. 20071583 20071590 20071593 20071597 20071598 20071601 Transactions Granted Early Termination—07/03/2007 20070837 ......................... Hanover Compressor Company ........ Universal Compression Holdings, Inc 20070838 ......................... 20071506 ......................... 20071511 ......................... Universal Compression Holdings, Inc KASLION S.a.r.L ............................... J&F Participacoes S.A ...................... 20071588 ......................... 20071599 ......................... Cleveland-Cliffs Inc ........................... C/R Stallion Investment Partnership, L.P. Hanover Compressor Company ........ DSP Group Inc .................................. Hicks, Muse, Tate & Furst Equity Fund V, L.P. PinnOak Resources, LLC .................. Terry G. Bailey .................................. 20071602 ......................... C/R Stallion Investment Partnership, L.P. Envirovac, Ltd .................................... Universal Compression Holdings, Inc. Hanover Compressor Company. DSP Group Inc. Swift Foods Company. PinnOak Resources, LLC. Salty’s Manufacturing, Ltd., Salty’s Well Hill No. 1, Ltd., Salty’s Well Parker No. 1, Ltd., Salty’s Well Service, Ltd. Salty’s Manufacturing, Ltd., Salty’s Well Hill No. 1, Ltd., Salty’s Well Johnson No. 1, Ltd., Salty’s Well Johnson No. 2, Ltd., Salty’s Well Johnson No. 3, Ltd., Salty’s Well Johnson No. 4, Ltd., Salty’s Well Nacogdoches 1, Ltd., Salty’s Well Panola 1, Ltd., Salty’s Well Parker No. 1, Ltd., Salty’s Well Service, Ltd., Salty’s Well Shelby No. 1, Ltd. Transactions Granted Early Termination—07/05/2007 20071519 ......................... Carlyle Partners IV, L.P .................... JP Morgan Chase & Co .................... Niagara Holdings, Inc. Transactions Granted Early Termination—07/06/2007 20071520 ......................... Saudi Basic Industries Corporation ... FOR FURTHER INFORMATION CONTACT: Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative. Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H– 303, Washington, DC 20580, (202) 326– 3100. By direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 07–3435 Filed 7–13–07; 8:45 am] BILLING CODE 6750–01–M hsrobinson on PROD1PC76 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Misconduct in Science AGENCY: ACTION: Office of the Secretary, HHS. Notice. VerDate Aug<31>2005 16:59 Jul 13, 2007 Jkt 211001 General Electric Company ................ SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Kristin Roovers, Ph.D., University of Pennsylvania: Based on an investigation conducted by the University of Pennsylvania (UP) and additional analysis and information obtained by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Kristin Roovers, Ph.D., former postdoctoral fellow, Departments of Medicine, Cell and Developmental Biology, and Pharmacology, and Howard Hughes Medical Institute, and former graduate student, Department of Pharmacology, UP, engaged in misconduct in science in research funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL061567, P50 HL057278, and T32 HL07873, National Institutes of Diabetes and Digestive and Kidney PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 GE Entities. Diseases (NIDDK), NIH, grants P30 DK52574 and R01 DK066886, National Cancer Institute (NCI), NIH, grant R01 CA72639, and National Institute of General Medical Sciences (NIGMS), NIH, grants R01 GM48224, R01 GM58224, R01 GM51878, and R01 GM69064. Dr. Roovers’ manipulations and falsification of data were extensive, encompassing 19 panels of Western blot data, appearing in 11 figures in 3 publications from her research as a graduate student and her first postdoctoral position and in 9 panels of immunoblot data in 8 figures of an unpublished manuscript. Specifically, the findings involved falsification by duplication and reuse of immunoblot data to misrepresent the results as data from different experiments that had been reported in the following manuscript and three publications: • Figures 2C, 3C, 4D, 4E, 6C, 7B, and supplement Figures 1, 2B, and 3B in a E:\FR\FM\16JYN1.SGM 16JYN1 38837 Federal Register / Vol. 72, No. 135 / Monday, July 16, 2007 / Notices manuscript submitted to the Journal of Clinical Investigation entitled: ‘‘Akt1 promotes physiologic, but antagonizes pathologic, cardiac growth.’’ • Figures 3A, 3C, and 4A in: Welsh, C.F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M.A., & Assoian, R.K. ‘‘Timing of cyclin D1 expression within G1 phase is controlled by Rho.’’ Nature Cell Biology 3(11):950–957, 2001. • Figures 1, 2A, 2B, 3A, 3C, 4A, 4B, 6C, 6D, and 6E in: Roovers, K., & Assoian, R.K. ‘‘Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases.’’ Mol. Cell Biol. 23(12):4283–4294, 2003. Retracted in Mol. Cell Biol. 26(13):5203, July 2006. • Figures 1C, 2C, 5B, 5D, 6B and 6D in: Roovers, K., Klein, E.A., Castagnino, P., & Assoian, R.K. ‘‘Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression.’’ Developmental Cell 5 (2):273–284, 2003. Retracted in Developmental Cell 10(5):681, May 2006. Corrections were recommended by UP for the Nature Cell Biology paper. Dr. Roovers’ falsified Western blot data from the publications in Nature Cell Biology and from Developmental Cell were included in NIH grant applications CA 72639–07 and GM 69064–01. ORI has implemented the following administrative actions for a period of five (5) years, beginning on June 7, 2007: (1) Dr. Roovers is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ as defined in HHS’ implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) Dr. Roovers is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. Chris B. Pascal, Director, Office of Research Integrity. [FR Doc. E7–13703 Filed 7–13–07; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–07–06BM] Agency Forms Undergoing Paperwork; Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an email to: omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Notice of Correction Title of Project Randomized Controlled Trial of Routine Screening for Intimate Partner Violence—New—National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC). Description of Correction A 30-day Federal Register Notice was published on June 25, 2007 (Vol. 72, No. 121, pp. 34691–34692) describing proposed activities with total estimated annualized burden of 717.7 hours. The annualized total burden hour estimate is correct, however, due to a clerical oversight, the table of Estimated Annualized Burden Hours contained non-annualized figures for the Number of Respondents (i.e., project totals). The corrected table appears below. The total estimated annualized burden hours are 717.7. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondents Form name Women Seeking Health Care Services .......... Eligibility Script for Pretest ............................. Baseline Questionnaire for Pretest ................ Follow-up Questionnaire Pretest .................... Eligibility Script for Main Study ...................... Baseline Questionnaire for Main Study ......... Follow-up Questionnaire Main Study ............. 70 65 59 1,533 1,227 860 Number of responses per respondent Average burden per response (in hours) 1 1 1 1 1 1 1/60 15/60 12/60 1/60 17/60 22/60 DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4163–18–P hsrobinson on PROD1PC76 with NOTICES Dated: July 9, 2007. Maryam I. Daneshvar, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E7–13730 Filed 7–13–07; 8:45 am] Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under Project: National Evaluation of the Protection and Advocacy for Individuals with Mental Illness (PAIMI) Program—NEW In recognition that systematic evaluation of this and other government programs are part of good management VerDate Aug<31>2005 16:59 Jul 13, 2007 Jkt 211001 Substance Abuse and Mental Health Services Administration PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 72, Number 135 (Monday, July 16, 2007)]
[Notices]
[Pages 38836-38837]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-13703]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Misconduct in Science

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Kristin Roovers, Ph.D., University of Pennsylvania: Based on an 
investigation conducted by the University of Pennsylvania (UP) and 
additional analysis and information obtained by the Office of Research 
Integrity during its oversight review, the U.S. Public Health Service 
(PHS) found that Kristin Roovers, Ph.D., former postdoctoral fellow, 
Departments of Medicine, Cell and Developmental Biology, and 
Pharmacology, and Howard Hughes Medical Institute, and former graduate 
student, Department of Pharmacology, UP, engaged in misconduct in 
science in research funded by National Heart, Lung, and Blood Institute 
(NHLBI), National Institutes of Health (NIH), grants R01 HL061567, P50 
HL057278, and T32 HL07873, National Institutes of Diabetes and 
Digestive and Kidney Diseases (NIDDK), NIH, grants P30 DK52574 and R01 
DK066886, National Cancer Institute (NCI), NIH, grant R01 CA72639, and 
National Institute of General Medical Sciences (NIGMS), NIH, grants R01 
GM48224, R01 GM58224, R01 GM51878, and R01 GM69064.
    Dr. Roovers' manipulations and falsification of data were 
extensive, encompassing 19 panels of Western blot data, appearing in 11 
figures in 3 publications from her research as a graduate student and 
her first postdoctoral position and in 9 panels of immunoblot data in 8 
figures of an unpublished manuscript.
    Specifically, the findings involved falsification by duplication 
and reuse of immunoblot data to misrepresent the results as data from 
different experiments that had been reported in the following 
manuscript and three publications:
     Figures 2C, 3C, 4D, 4E, 6C, 7B, and supplement Figures 1, 
2B, and 3B in a

[[Page 38837]]

manuscript submitted to the Journal of Clinical Investigation entitled: 
``Akt1 promotes physiologic, but antagonizes pathologic, cardiac 
growth.''
     Figures 3A, 3C, and 4A in: Welsh, C.F., Roovers, K., 
Villanueva, J., Liu, Y., Schwartz, M.A., & Assoian, R.K. ``Timing of 
cyclin D1 expression within G1 phase is controlled by Rho.'' Nature 
Cell Biology 3(11):950-957, 2001.
     Figures 1, 2A, 2B, 3A, 3C, 4A, 4B, 6C, 6D, and 6E in: 
Roovers, K., & Assoian, R.K. ``Effects of rho kinase and actin stress 
fibers on sustained extracellular signal-regulated kinase activity and 
activation of G(1) phase cyclin-dependent kinases.'' Mol. Cell Biol. 
23(12):4283-4294, 2003. Retracted in Mol. Cell Biol. 26(13):5203, July 
2006.
     Figures 1C, 2C, 5B, 5D, 6B and 6D in: Roovers, K., Klein, 
E.A., Castagnino, P., & Assoian, R.K. ``Nuclear translocation of LIM 
kinase mediates Rho-Rho kinase regulation of cyclin D1 expression.'' 
Developmental Cell 5 (2):273-284, 2003. Retracted in Developmental Cell 
10(5):681, May 2006.
    Corrections were recommended by UP for the Nature Cell Biology 
paper.
    Dr. Roovers' falsified Western blot data from the publications in 
Nature Cell Biology and from Developmental Cell were included in NIH 
grant applications CA 72639-07 and GM 69064-01.
    ORI has implemented the following administrative actions for a 
period of five (5) years, beginning on June 7, 2007:
    (1) Dr. Roovers is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility or involvement in nonprocurement programs of the United 
States Government referred to as ``covered transactions'' as defined in 
HHS' implementation of OMB Guidelines to Agencies on Governmentwide 
Debarment and Suspension at 2 CFR part 376, et seq.; and
    (2) Dr. Roovers is prohibited from serving in any advisory capacity 
to PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

Chris B. Pascal,
Director, Office of Research Integrity.
 [FR Doc. E7-13703 Filed 7-13-07; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.